| BMC Ophthalmology | |
| Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis | |
| Research | |
| Arslan Tsai1  Pei-Chang Wu2  Wen-Chuan Wu3  Chien-Liang Wu4  Cheng-Kuo Cheng5  Ching-Yao Tsai6  Yun-Dun Shen7  Jiann-Torng Chen8  | |
| [1] Clinical Development and Medical Affairs, Novartis Taiwan, Taipei City, Taiwan;Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan;Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan;Park One International Hospital, Kaohsiung City, Taiwan;Municipal Wan Fang Hospital, Taipei City, Taiwan;Shin Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan;Taipei City Hospital, Taipei City, Taiwan;Institute of Public Health, National Yang Ming Chiao Tung University, Taipei City, Taiwan;Department of Business Administration, Fu Jen Catholic University, New Taipei City, Taiwan;Taipei Medical University-Shung Ho Hospital, New Taipei City, Taiwan;Kang-Ning General Hospital, Taipei City, Taiwan;Tri-Service General Hospital, Chenggong Road, Taipei City 114, Taiwan;National Defense Medical Center, Taipei City, Taiwan; | |
| 关键词: Anti-VEGF; BCVA; Clinical practice; CRT; nAMD; RACER; Ranibizumab; Real-world; Taiwan; Treatment switch; Treatment response; | |
| DOI : 10.1186/s12886-023-02780-0 | |
| received in 2022-08-30, accepted in 2023-01-11, 发布年份 2023 | |
| 来源: Springer | |
PDF
|
|
【 摘 要 】
BackgroundThe Ranibizumab AMD Clinical Efficacy Study (RACER) conducted in treatment-naive adult Taiwanese patients with neovascular age-related macular degeneration (nAMD) suggested the importance of early and intensive dosing of ranibizumab for optimal treatment outcomes. This subgroup analysis aims to provide clinical information on treatment response that can potentially guide on maintaining the treatment or switching anti-VEGF agents in the real-world setting.MethodsVisual acuity (VA) and central retinal thickness (CRT) were assessed in the RACER subgroup population. Subgroup analysis sets were categorised based on: (1) baseline best-corrected VA (BCVA; ≤ 48 and > 48 letters); (2) baseline CRT (≤ 325 or > 325 μm); and (3) treatment response after three monthly initial injections: < or ≥ 5-letter gain in BCVA and reduction of < or ≥ 50 μm in CRT.ResultsPatient age, sex, nAMD duration and number of ranibizumab injections did not differ significantly between the treatment subgroups. Poor baseline BCVA (≤ 48 letters) and baseline CRT severity (> 325 µm) were predictors of maximum BCVA gains (9.6 ± 12.9 letters [95%CI: 6.3 to 12.9] and 5.1 ± 18.3 letters [95%CI: − 0.5 to 10.8] at Months 3 and 12, respectively) and better CRT reductions (− 127.6 ± 104.2 µm and − 104.2 ± 107.4 µm at Months 3 and 12, respectively; both P < 0.001). For the subgroup showing favourable treatment improvement with BCVA gains ≥ 5 letters after three monthly initial injections, 75.6% of patients maintained follow-up at Month 12 with a mean of 6.5 ± 14.3 letter gains (95% CI: 1.2 to 11.7). The BCVA gains < 5-letter subgroup nevertheless had stable BCVA (0.4 ± 12.1 letter gains) and CRT (− 41.9 ± 61.2 µm) at Month 12, respectively. In the subgroup with ≥ 50 µm CRT reduction after three monthly initial injections, there are significantly higher BCVA improvements vs. the < 50 µm CRT reduction subgroup at Month 3 (5.0 ± 8.6 letter gains vs. 1.5 ± 11.6 letter gains, respectively; intergroup P = 0.005).ConclusionLower baseline BCVA and higher baseline CRT were associated with BCVA gains and CRT reductions throughout the 12-month study period. Early CRT improvements after three monthly initial injections were associated with BCVA gains as early as Month 3.
【 授权许可】
CC BY
© The Author(s) 2023
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202305114775264ZK.pdf | 1862KB | ||
| Fig. 2 | 1878KB | Image | |
| MediaObjects/41408_2022_766_MOESM3_ESM.pdf | 219KB | ||
| Fig. 1 | 35KB | Image | |
| 42004_2022_800_Article_IEq73.gif | 1KB | Image | |
| MediaObjects/12888_2023_4533_MOESM1_ESM.docx | 14KB | Other |
【 图 表 】
42004_2022_800_Article_IEq73.gif
Fig. 1
Fig. 2
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
PDF